GLAXO responds to drug court Rawalpindi judgment

In a notification sent to PSX on 24/04/2024, GlaxoSmithKline Pakistan Limited (GLAXO) has announced its legal position on the GLAXO drug case judgment.

We would like to inform you that the Drug Court Rawalpindi has passed judgement dated April 22, 2024, in Case Judicial No. 4229/DC/Rwp/22 against the current and former officers of GSK under the Drugs Act 1976 related to the provision of sub-standard drugs.

GSK as well as the officers impleaded in the proceedings hereby deny any sort of wrong doing in the matter and are taking immediate steps to challenge the aforementioned judgment before the appellate forum. We would also like to inform you that GSK will keep all stakeholders abreast of any significant updates in this regard.

---

📢 Announcement: We're on WhatsApp – Join Us There! 

Here's what you get:

• Member-Only Discussion Community
• Research Reports with Explanations & Expert Views
• Access to Exclusive KSEStocks Market Reports
• Model Portfolio with Clear Investment Rationale
• Monthly Portfolio Review & Health Check
• On-Demand Stock Coverage Requests
• PSX Facilitation (CDC Account, Share Transfer, Physical Conversion)

The shares of GLAXO were last trading at Rs. 98.89 today.

⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →